The rationale for using FASN inhibitors in combination with chemotherapy derives from the well known cellular effects of FASN inhibition such as: the palmitate synthesis blockade, alteration of plasma membrane structure, oncogenic signal transduction inhibition (e.g. β-catenin, Wnt, and Akt signalling), gene expression reprogramming, and tumor cell apoptosis induction (Mullen and Yet, 2015). This evidence concerns the gene AKT1 and neoplasm.